Current Report Filing (8-k)

0001280600false00012806002021-11-042021-11-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

___________________________

 

FORM 8-K

___________________________

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  November 4, 2021

 ___________________________

 

ACCELERON PHARMA INC.

(Exact name of Registrant as specified in its charter)

 

Delaware

001-36065

27-0072226

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification Number)

128 Sidney Street

Cambridge,

MA

02139

(Address of principal executive offices)

(Zip Code)

 

Registrant’s telephone number, including area code:  [phone]

 

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class			Ticker Symbol(s)			Name of each exchange on which registered
Common Stock, $0.001 per share			XLRN			The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company            ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.            ☐

---

Item 2.02    Results of Operations and Financial Condition.

 

On November 4, 2021, Acceleron Pharma Inc. issued a press release announcing its financial results for the fiscal quarter ended September 30, 2021.  A copy of the press release is furnished as Exhibit 99.1 hereto.

 

The information contained in this Item, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing.

Item 9.01    Financial Statements and Exhibits.

 

    (d)    Exhibits.

        

Exhibit Number						Description of Exhibit
99.1						Press Release of Acceleron Pharma Inc. dated November 4, 2021
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

---

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

			ACCELERON PHARMA INC.
			By:			/s/ Adam M. Veness, Esq.
						Adam M. Veness, Esq.
						Senior Vice President, General Counsel and Secretary
Date: November 4, 2021

3